Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B-Reference-Cited by-同舟云学术

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B

Published:2021-05-06 Issue:4 Volume:27 Page:574-580
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Mahlangu Johnny¹^ORCID,Levy Howard²^ORCID,Lee Martin³,Del Greco Frank²

Affiliation:

1. Haemophilia Comprehensive Care Center Charlotte Maxeke Johannesburg Academic Hospital, and University of the Witwatersrand Johannesburg South Africa

2. Catalyst Biosciences San Francisco CA USA

3. Fielding School of Public Health University of California Los Angeles Los Angeles CA USA

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14315

Reference18 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Haemophilia B: Christmas disease

3. Prophylaxis for severe haemophilia: clinical and economical issues

4. Prophylactic infusion regimens in the management of hemophilia;Ljung RC;Thromb Haemost,1999

5. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor IX stimulants in preclinical and early phase trials for hemophilia B treatment;Expert Opinion on Investigational Drugs;2024-08-11

2. Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques;Molecular Therapy;2024-07

3. Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration;Journal of Thrombosis and Haemostasis;2024-07

4. Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors;Clinical Pharmacology & Therapeutics;2024-01-16

5. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency);Expert Opinion on Biological Therapy;2023-11-23